Search

Your search keyword '"CENDERELLO, GIOVANNI"' showing total 7 results
Start Over Author "CENDERELLO, GIOVANNI" Journal aids london england
7 results on '"CENDERELLO, GIOVANNI"'

1. Cancer in people with multidrug-resistant HIV.

Author

Clemente T, Pontillo D, Malagnino V, Calza L, Di Biagio A, Cenderello G, Lolatto R, Manzillo E, Moioli MC, De Socio GV, Castagna A, and Spagnuolo V

Subjects
Humans, Male, Female, Adult, Retrospective Studies, Incidence, Middle Aged, Risk Factors, HIV Infections complications, HIV Infections drug therapy, Neoplasms, Drug Resistance, Multiple, Viral
Abstract

Retrospective, cohort analysis including people with HIV and 4-class drug resistance (4DR). The 8-year probability of malignancy after first evidence of 4DR was 12%, with an incidence of 1.6/100 person years of follow-up. Cancer risk tended to increase with higher precancer viremia copy-years adjusted for time [per 1 - log10 copies/ml higher: adjusted hazard ratio (aHR) = 1.35; 95% confidence interval (95% CI) = 0.98-1.85] and male sex-assigned-at-birth (aHR = 2.50; 95% CI = 0.86-7.27). Efforts to achieve long-term undetectability, risk factor control, prevention, and more aggressive cancer screening are needed in this fragile population., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

2. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?

Author

Bartalucci C, Baldi F, Ricci E, Orofino G, Menzaghi B, Ferrara S, Pellicano' GF, Squillace N, Sarchi E, Pontali E, Cenderello G, Bargiacchi O, Piccica M, Carleo MA, Cascio A, De Socio GV, Bonfanti P, and Di Biagio A

Subjects
Adult, Humans, Anti-Retroviral Agents, Italy, Rilpivirine, HIV Infections drug therapy, Pyridones, Diketopiperazines
Abstract

Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

3. Factors associated with hospital admission for COVID-19 in HIV patients.

Author

Di Biagio A, Ricci E, Calza L, Squillace N, Menzaghi B, Rusconi S, Orofino G, Bargiacchi O, Molteni C, Valsecchi L, Cenderello G, Ferrara S, Saracino A, Maggi P, Falasca K, Taramasso L, and Bonfanti P

Subjects
Antiviral Agents therapeutic use, Betacoronavirus, CD4 Lymphocyte Count, COVID-19, Coronavirus Infections drug therapy, Coronavirus Infections physiopathology, Female, HIV Infections drug therapy, Humans, Hydroxychloroquine therapeutic use, Italy, Male, Middle Aged, Pandemics, Pneumonia, Viral drug therapy, Pneumonia, Viral physiopathology, Risk Factors, SARS-CoV-2, Coronavirus Infections complications, HIV Infections complications, Hospitalization, Pneumonia, Viral complications
Abstract

: This study reports on hospital admission and outcomes of 69 HIV-infected individuals who were diagnosed with SARS-CoV-2 infection between February and May 2020, in a network of Italian centres. Patients' characteristics and median days between symptoms and diagnosis were similar by hospital admission, whereas admitted patients had lower nadir CD4 cells and current lymphocytes count. These values were also correlated to worse COVID-19 outcome. Antiretroviral drugs did not seem to be associated with disease severity.

Published
2020
Full Text
View/download PDF

6. Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients.

Author

Dentone C, Di Biagio A, Parodi A, Bozzano F, Fraccaro P, Signori A, Cenderello G, Mantia E, Orofino G, De Maria A, Filaci G, and Fenoglio D

Subjects
Adult, Antigens, CD analysis, Biomarkers analysis, Case-Control Studies, Cross-Sectional Studies, Female, HLA Antigens analysis, Humans, Killer Cells, Natural chemistry, Male, Maraviroc, Middle Aged, Monocytes chemistry, Treatment Outcome, Anti-Retroviral Agents therapeutic use, Cyclohexanes therapeutic use, HIV Infections drug therapy, HIV Infections immunology, Killer Cells, Natural immunology, Monocytes immunology, Triazoles therapeutic use
Abstract

This is a cross-sectional, case-control study analyzing the effect of antiretroviral therapy (ART) including or not maraviroc, on circulating monocytes and natural killer cells. Sixty-eight HIV-positive patients virologically suppressed receiving ART at least 6 months were subdivided as receiving (group 1) or not (group 2) maraviroc in their ART. Frequency of monocytes and natural killer cells, as well as their activation markers, were studied. Modulation of innate immune cells may be differently affected by combined ART.

Published
2014
Full Text
View/download PDF

7. Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.

Author

Di Biagio A, Rosso R, Bruzzone B, Cenderello G, Dentone C, Mularoni A, Ferrea G, Icardi G, and Viscoli C

Subjects
Carbamates pharmacology, Darunavir, Drug Therapy, Combination, Furans, HIV Infections virology, HIV Protease Inhibitors pharmacology, HIV-1 genetics, Humans, Reverse Transcriptase Inhibitors therapeutic use, Ritonavir therapeutic use, Sulfonamides pharmacology, Treatment Failure, Treatment Outcome, Carbamates therapeutic use, Drug Resistance, Viral genetics, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, HIV-1 drug effects, Mutation, Sulfonamides therapeutic use
Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results